Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2023 Filed Feb 16, 2023 21:18 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 20 | $296.48 | $5,929.60 |
DisclosureSEC source: 0001209191-23-010061 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,674 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:18 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 71 | $295.89 | $21,008.19 |
DisclosureSEC source: 0001209191-23-010061 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,694 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.36 to $296.32). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:49 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 500 | $300.23 | $150,115.00 |
DisclosureSEC source: 0001209191-23-009174 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,396 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $300.23 (range $299.96 to $300.63). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:49 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,893 | $299.36 | $566,688.48 |
DisclosureSEC source: 0001209191-23-009174 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,896 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $299.36 (range $298.86 to $299.83). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:49 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 2,160 | $298.47 | $644,695.20 |
DisclosureSEC source: 0001209191-23-009174 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,789 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $298.47 (range $297.85 to $298.82). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:49 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 245 | $296.44 | $72,627.80 |
DisclosureSEC source: 0001209191-23-009174 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,949 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $296.44 (range $295.84 to $296.57). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:49 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 5,990 | $298.26 | $1,786,577.40 |
DisclosureSEC source: 0001209191-23-009174 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,194 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:53 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 835 | $300.13 | $250,608.55 |
DisclosureSEC source: 0001209191-23-009182 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,003 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $300.13 (range $299.93 to $300.53). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:53 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 1,779 | $299.26 | $532,383.54 |
DisclosureSEC source: 0001209191-23-009182 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,838 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $299.26 (range $298.86 to $299.81). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:53 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 2,028 | $298.42 | $605,195.76 |
DisclosureSEC source: 0001209191-23-009182 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,617 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $298.42 (range $297.85 to $298.80). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:53 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 245 | $296.44 | $72,627.80 |
DisclosureSEC source: 0001209191-23-009182 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,645 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $296.44 (range $295.84 to $296.57). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:53 UTC |
Arbuckle Stuart AEVP, COO
|
Tax withholdingCommon Stock | 5,990 | $298.26 | $1,786,577.40 |
DisclosureSEC source: 0001209191-23-009182 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,890 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:55 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 4,992 | $298.26 | $1,488,913.92 |
DisclosureSEC source: 0001209191-23-009190 · doc4.xml · nonDerivative · entry 2 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,265 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:58 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 5,990 | $298.26 | $1,786,577.40 |
DisclosureSEC source: 0001209191-23-009198 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,714 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:01 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Tax withholdingCommon Stock | 13,344 | $298.26 | $3,979,981.44 |
DisclosureSEC source: 0001209191-23-009211 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,079 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:06 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Tax withholdingCommon Stock | 4,657 | $298.26 | $1,388,996.82 |
DisclosureSEC source: 0001209191-23-009226 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,484 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:08 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 113 | $300.39 | $33,944.07 |
DisclosureSEC source: 0001209191-23-009232 · doc4.xml · nonDerivative · entry 3 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,915 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $300.39 (range $300.00 to $300.79). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:08 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
Tax withholdingCommon Stock | 4,340 | $298.26 | $1,294,448.40 |
DisclosureSEC source: 0001209191-23-009232 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,028 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 11 | $300.79 | $3,308.69 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 7 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,765 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 64 | $299.88 | $19,192.32 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 6 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,776 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $299.88 (range $299.62 to $300.53). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 120 | $298.98 | $35,877.60 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,840 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $298.98 (range $298.53 to $299.50). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 78 | $298.11 | $23,252.58 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,960 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $298.11 (range $297.51 to $298.50). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 2 | $295.84 | $591.68 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,038 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 2,995 | $298.26 | $893,288.70 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,040 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:15 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 4,992 | $298.26 | $1,488,913.92 |
DisclosureSEC source: 0001209191-23-009243 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,191 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:49 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 3,461 | $294.33 | $1,018,676.13 |
DisclosureSEC source: 0001209191-23-009174 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,184 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:53 UTC |
Arbuckle Stuart AEVP, COO
|
Tax withholdingCommon Stock | 3,372 | $294.33 | $992,480.76 |
DisclosureSEC source: 0001209191-23-009182 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,880 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:55 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 2,707 | $294.33 | $796,751.31 |
DisclosureSEC source: 0001209191-23-009190 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,257 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:58 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 3,372 | $294.33 | $992,480.76 |
DisclosureSEC source: 0001209191-23-009198 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,704 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:06 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Tax withholdingCommon Stock | 2,611 | $294.33 | $768,495.63 |
DisclosureSEC source: 0001209191-23-009226 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,141 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:08 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
Tax withholdingCommon Stock | 902 | $294.33 | $265,485.66 |
DisclosureSEC source: 0001209191-23-009232 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,368 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:12 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 1,377 | $294.33 | $405,292.41 |
DisclosureSEC source: 0001209191-23-009237 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,035 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:15 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 2,707 | $294.33 | $796,751.31 |
DisclosureSEC source: 0001209191-23-009243 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,183 Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:53 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,304 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-23-007827 · doc4.xml · derivative · entry 8 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,304 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:53 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 153 | $309.06 | $47,286.18 |
DisclosureSEC source: 0001209191-23-007827 · doc4.xml · nonDerivative · entry 7 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,645 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $309.06 (range $308.76 to $309.42). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:53 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 620 | $306.70 | $190,154.00 |
DisclosureSEC source: 0001209191-23-007827 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,798 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $306.70 (range $306.32 to $307.25). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:53 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 349 | $305.08 | $106,472.92 |
DisclosureSEC source: 0001209191-23-007827 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,418 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $305.08 (range $304.72 to $305.43). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:53 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 100 | $303.64 | $30,364.00 |
DisclosureSEC source: 0001209191-23-007827 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,767 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $303.64 (range $303.37 to $304.27). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:53 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 70 | $302.00 | $21,140.00 |
DisclosureSEC source: 0001209191-23-007827 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,867 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:53 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 12 | $300.39 | $3,604.68 |
DisclosureSEC source: 0001209191-23-007827 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,937 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:53 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock | 1,304 | $187.53 | $244,539.12 |
DisclosureSEC source: 0001209191-23-007827 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 21:53 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Tax withholdingCommon Stock | 3,578 | $317.83 | $1,137,195.74 |
DisclosureSEC source: 0001209191-23-006958 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,423 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:30 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006869 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,645 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:30 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantCommon Stock | 12,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006869 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,779 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:30 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantCommon Stock | 12,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006869 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,465 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:32 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
GrantCommon Stock | 2,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006879 · doc4.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,012 F2 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:32 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
GrantCommon Stock | 2,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006879 · doc4.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,062 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:36 UTC |
Arbuckle Stuart AEVP, COO
|
GrantCommon Stock | 11,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006894 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,252 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:36 UTC |
Arbuckle Stuart AEVP, COO
|
GrantCommon Stock | 14,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006894 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,043 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:36 UTC |
Arbuckle Stuart AEVP, COO
|
GrantCommon Stock | 12,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006894 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,419 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.